European biologics market is estimated to grow at a CAGR of 7.9% during the forecast period. The major factors contributing to the market growth include the rising approvals of monoclonal antibody drugs and a significant rise in the prevalence of chronic diseases. As per the European Commission, the cancer burden is estimated to have increased to 2.7 million new incidences in EU-27 countries (all kinds, apart from non-melanoma skin cancer) in 2020. This, in turn, is leading to an increasing demand for biologics drugs which acts as an immune system substance that supports to augment the body’s ability to fight against cancer. Types of biological drugs comprise vaccines, allergens, blood, tissues, recombinant proteins, blood components, cells, and genes. Biologic drugs are utilized to treat multiple conditions and are the most available advanced therapies. Apart from cancer, biologic drugs are utilized for the treatment of ulcerative colitis, rheumatoid arthritis, Crohn's disease, and other autoimmune diseases.

Visit for Global Biologics Market Report at: https://www.omrglobal.com/industry-reports/biologics-market

European biologics market is segmented based on product and application. Based on the product, the market is segmented into antibody therapeutics, vaccines, cell therapy, gene therapy, and others. Increasing focus on approvals of gene therapies is driving the growth of the market. In September 2020, GenSight Biologics presented a marketing application for Lumevoq, its lead gene therapy to the European Medicines Agency (EMA). The company intends to seek approval for Lumevoq (lenadogene nolparvovec) as a therapy for patients suffering from vision loss resulted due to Leber Hereditary Optic Neuropathy (LHON), caused by a mutation in the ND4 mitochondrial gene. Based on application, the market is segmented into cancer, autoimmune diseases, infectious diseases, and others. 

Some key players in the market include AbbVie Inc., Amgen Inc., Eli Lilly and Co., F. Hoffman-La Roche AG, and Boehringer Ingelheim GmbH. The market players are focusing on strategic initiatives to gain a significant market share. For instance, in June 2018, Boehringer Ingelheim declared its plans to invest nearly $269.2 million into a new biological development scenter (BDC) at the company’s R&D site in Biberach, Germany. The center is a major building block that encourages the company’s long-term strategy to enhance the share of pipeline’s biologicals.

Research Methodology

The market study of the European biologics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. European Biologics Market Research and Analysis by Product
2. European Biologics Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the European biologics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European biologics market.
• Insights about market determinants which are stimulating the European biologics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.